Characterization of recombinant hERG K+ channel inhibition by the active metabolite of amiodarone desethyl-amiodarone

Y.H. Zhang, H. Cheng, V.A. Alexeenko, C.E. Dempsey, J.C. Hancox

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of this study was to determine the effects of desethyl-amiodarone (DEA), the major metabolite of the class III antiarrhythmic drug amiodarone, on human ether-à-go-go-related gene (hERG) encoded potassium channel current. Materials and methods: Whole-cell patch clamp recordings were made at 37°C of ionic current (IhERG) carried by recombinant hERG channels expressed in HEK-293 cells. Results: Desethyl-amiodarone inhibited IhERG with a half-maximal inhibitory concentration of approximately 158 nmol/L, compared with approximately 47 nmol/L for amiodarone. The inhibitory action of DEA on IhERG was contingent on channel gating, showing significant time and voltage dependence. Desethyl-amiodarone also produced an approximately -9 mV shift in the voltage dependence of activation of IhERG; however, there was no significant preference for activated over inactivated channels. Conclusions: Because hERG underlies native cardiac "IKr" channels, hERG/IKr inhibition by DEA as well as amiodarone may contribute to the overall effects of amiodarone administration on cardiac repolarization. © 2010 Elsevier Inc. All rights reserved.
Original languageUndefined
Pages (from-to)440-448
Number of pages9
JournalJournal of Electrocardiology
DOIs
Publication statusPublished - 2010

Keywords

  • Amiodarone
  • Antiarrhythmic
  • Class III
  • Desethyl-amiodarone
  • HERG
  • Human ether-à-go-go-related gene
  • Potassium channel
  • QT interval

Cite this